Arteris, INC Form 4 insider transactions

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, reported the sale of 6,258 shares of common stock in early July 2025, primarily to cover tax liabilities from restricted stock unit releases and through a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, reported the sale of 8,837 shares of common stock in early July 2025, primarily to cover tax obligations from restricted stock units and through a pre-established 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 294 shares of common stock on July 1, 2025, through a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Saiyed Atiq Raza has filed a Form 4 indicating a pre-planned sale of 19,809 shares of common stock on June 27, 2025, at a weighted average price of $10.0203 per share, executed under a Rule 10b5-1 trading plan.

Arteris, Inc. President and CEO, Charles Janac, reported the sale of 21,286 shares of common stock in two separate transactions in late June and early July 2025, executed under pre-established 10b5-1 trading plans.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold a total of 11,276 shares of common stock in two transactions in late June and early July 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold a total of 11,276 shares of common stock over two days in June 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Saiyed Atiq Raza reported a transfer of 19,287 shares of common stock from direct ownership to a revocable family trust, maintaining his overall beneficial interest.

Nicholas B. Hawkins, VP and Chief Financial Officer of Arteris, Inc., reported the sale of 3,770 shares of common stock on June 9, 2025, as part of a pre-scheduled 10b5-1 trading plan.

Arteris, Inc. Director Antonio J. Viana disclosed the sale of 19,287 shares of common stock and the transfer of 21,327 shares to a family trust.

Paul L. Alpern, VP and General Counsel of Arteris, Inc., sold 423 shares of common stock for a weighted average price of $7.6618 per share, as part of a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Charles Janac, reported the sale of 2,057 shares of common stock on June 4, 2025, as part of a pre-established 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold a total of 2,451 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 202 shares of common stock for $7.96 per share on June 4, 2025, as part of a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Joachim Kunkel has reported the acquisition of 20,839 restricted stock units (RSUs) as part of his compensation, increasing his beneficial ownership to 64,595 shares.

Arteris, Inc. Director Antonio J. Viana reported the acquisition of 20,839 restricted stock units (RSUs) on June 3, 2025, as part of his compensation.

Arteris, Inc. Director Claudia F. Munce was granted 20,839 restricted stock units (RSUs) on June 3, 2025, increasing her direct beneficial ownership to 100,851 shares.

Arteris, Inc. Director Raman Chitkara has acquired 20,839 restricted stock units, increasing his beneficial ownership to 157,867 shares.

Arteris, Inc. Director Saiyed Atiq Raza has reported the acquisition of 20,839 restricted stock units (RSUs) on June 3, 2025, as part of his compensation.

Arteris, Inc. Director Wayne C. Cantwell has reported the acquisition of 34,732 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, reported the sale of 438 shares of common stock to satisfy tax obligations arising from restricted stock unit release, while his total beneficial ownership remains substantial.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 612 shares of common stock at $7.7033 per share to satisfy tax obligations related to restricted stock unit vesting.

Arteris, Inc. President and CEO, K. Charles Janac, reported the sale of 1,246 shares of common stock to satisfy tax liabilities arising from the vesting of restricted stock units.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold 259 shares of common stock on June 2, 2025, to cover tax obligations related to restricted stock units.

Arteris, Inc.'s CFO, Nicholas B. Hawkins, executed a sale of 11,000 shares of common stock at an average price of $7.5405, pursuant to a pre-arranged 10b5-1 trading plan.

Director Joachim Kunkel acquired 1,834 shares of Arteris, Inc. common stock on April 5, 2025, as compensation in lieu of cash retainer fees.

Arteris, Inc. CEO Charles Janac sold shares of common stock on April 2nd and 3rd, 2025, to cover tax liabilities related to the release of restricted stock units.

Nicholas Hawkins, CFO of Arteris, Inc., sold shares of common stock on April 2nd and 4th, 2025, to cover tax liabilities related to the release of restricted stock units.

Laurent R. Moll, Chief Operating Officer of Arteris, Inc., sold shares of common stock on April 2nd and 4th, 2025, to cover tax liabilities related to the release of restricted stock units.

Paul Alpern, VP and General Counsel of Arteris, Inc., sold shares of common stock on April 2nd and 4th, 2025, to cover tax liabilities related to the release of restricted stock units.